SCHEMBL358341

SCHEMBL358341

COCCOCCOC(=O)NC(CC(C)C)C(=O)NC(Cc1ccccc1)C(=O)C(=O)NC1CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 7/20 1.00
CTSL P07711 2/20 0.49
CTSB P07858 1/20 0.49
CTSK P43235 6/20 0.48
HTRA1 Q92743 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873431 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL20873408 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL3838718 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL3837585 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL356129 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL19553159 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL3838115 1.00 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL20873413 0.97 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL20880308 0.97 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1
SCHEMBL3838750 0.97 CAPN1 (1.00) CAPN1CTSLCTSBCTSKHTRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190125714-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) 2019-05-02 US claimed
EP-3452034-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca (ES) 2019-03-13 EP claimed
WO-2017190894-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) 2017-11-09 WO claimed
EP-3452034-B1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA (ES) 2024-05-15 EP disclosed
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder OSAKA CITY UNIVERSITY (JP) 2023-12-19 US disclosed
US-20190314320-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER OSAKA CITY UNIVERSITY (JP) 2019-10-17 US disclosed
US-20190125714-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) 2019-05-02 US disclosed
EP-3466421-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER Osaka City University (JP) 2019-04-10 EP disclosed
EP-3452034-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca (ES) 2019-03-13 EP disclosed
US-20190030114-A1 ISOFORM-SPECIFIC CALPAIN INHIBITORS, METHODS OF IDENTIFICATION, AND USES THEREOF WESTERN UNIVERSITY OF HEALTH SCIENCES (US) 2019-01-31 US disclosed
WO-2017190894-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (ES) 2017-11-09 WO disclosed
CN-107018651-A Isotype specific calpain inhibitor and its recognition methods and purposes 健康科学西部大学 2017-08-04 CN disclosed
US-8697746-B2 Solid dispersion of alpha-ketoamide derivatives SENJU PHARMACEUTICAL CO., LTD. (JP) 2014-04-15 US disclosed
EP-2593089-A1 SOLID DISPERSION OF ALFA-KETOAMIDE DERIVATIVES Senju Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20120016020-A1 SOLID DISPERSION OF ALPHA-KETOAMIDE DERIVATIVES SENJU PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 US disclosed
WO-2012008159-A1 SOLID DISPERSION OF ALFA-KETOAMIDE DERIVATIVES SENJU PHARMACEUTICAL CO., LTD. (JP) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314320-A1 COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER PMP22, PRPH, NGF CAPN1 4158/4885CTSL 4677/4885CTSB 3143/4885
US-20190030114-A1 ISOFORM-SPECIFIC CALPAIN INHIBITORS, METHODS OF IDENTIFICATION, AND USES THEREOF CAPN1, CAPNS1, CAPN2 CAPN1 1/4885CTSL 506/4885CTSB 512/4885
US-20190125714-A1 CALPAIN INHIBITORS IN THE PREVENTION AND/OR TREATMENT OF VENTRICULAR REMODELLING CAPNS1, CAPN9, CAPN1 CAPN1 3/4885CTSL 149/4885CTSB 61/4885
US-11844776-B2 Composition for treatment and/or prevention of peripheral nerve disorder PMP22, PRPH, NGF CAPN1 4158/4885CTSL 4677/4885CTSB 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.